News

The study, known as BRAVE-AA-PEDS, was sponsored by Eli Lilly and Company and involved 257 adolescents aged 12 to under 18 years.

Bobbie expects the launch of their USDA Organic Whole Milk Infant formula to begin in April 2025.

A presentation at the 46th National Association of Pediatric Nurse Practitioners (NAPNAP) conference explored the role of biologics in pediatric care, their applications in various conditions, and safety considerations for clinicians.

The newest tapinarof results were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

A quick look into some of the top sessions occurring at the NAPNAP National Conference, being held from March 10-13, 2025 in Chicago, IL.

Jay T. Rubinstein, MD, PhD, highlighted promising CHORD trial data showing that DB-OTO gene therapy has led to hearing improvements in treated participants.

An overview of commercially available infant cardiorespiratory monitors and pulse oximeters in the home.

After 9.5 months, 94% of participants reported an improvement in incontinence symptoms, with 58% experiencing complete resolution and 18 (36%) reporting greater than 50% reduction in the number of accidents.

The newly-approved indication is for children aged 4 years and older who weigh 33 < 66 lbs, expanding on the August 9, 2024 approval in children at least 66 lbs.

According to data presented at AAAAI, berotralstat demonstrated a well tolerated safety profile and early and sustained reductions in monthly HAE attacks among patients aged 2 to under 12 years.

Mike Hennessy Jr, President and CEO of MJH Life Sciences kicks off our March Mental Health issue with a look into the ongoing pediatric mental health crisis.

First approved for PNH in 2007, the monoclonal antibody is now the first and only treatment for pediatric patients living with gMG.

On World Obesity Day, take this short quiz and test your knowledge of the AAP's clinical practice guideline to evaluate and treat children and adolescents with obesity.

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.

Colleen Sloan, PA-C, RDN, emphasizes the importance of learning to spot added sugars, compare portion sizes, and recognize misleading marketing claims to give patients a practical tool to take ownership of their health.

In this Q+A interview, Matthew Greenhawt, MD, breaks down a poster presentation from AAAAI / WAO joint congress meeting, highlighting increasing EoE incidence and prevalence.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The expanded indication now includes children aged 5 through 11 years, in addition to patients aged 12 to 65 years.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from February 2025.

"The measles outbreak that is currently happening in Texas and New Mexico is occurring in an area of the states that have very high anti-vaccine sentiments," Tan said.

A study finds air lead exposure increases infant mortality, linking emissions to low birthweight, SUID, and respiratory issues, urging stricter regulations.

Metformin does not influence breastfeeding rates in patients with type 2 or early diabetes, according to recent data.

"Vaccines are our absolute best defense for protecting people of all ages against many serious infectious diseases," Tan said in a statement as president of IDSA.

The application is for children aged 2 to 5 years with mild-to-moderate atopic dermatitis.

Find out how you did on the quiz.

In this quiz, we test your knowledge of the AAP's new algorithm and updated recommendations for newborn screening for critical congenital heart disease.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, breaks down key highlights of the latest double issue of Contemporary Pediatrics.

The human, pasteurized human milk fortifier is approved for term infants (> 37 weeks) following corrective surgery for the gastrointestinal disorder gastroschisis.

Updated data from the phase 1/2 CHORD trial in 12 children with profound genetic hearing loss were presented at the Association for Research in Otolaryngology’s 48th Annual MidWinter Meeting.

Nearly 40% of children treated with roflumilast cream 0.05% achieved a 75% improvement in EASI-75.